文献速递银屑病与炎症性皮肤病

中重度斑块状银屑病新型疗法的长期疗效:PASI应答的系统评价与网络Meta分析

Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-10-31

该研究通过系统评价与网络Meta分析比较中重度斑块状银屑病新型系统疗法在约1年时的PASI应答。主要分析纳入4项52周随机对照试验,显示布罗达鲁单抗显著优于司库奇尤单抗、乌司奴单抗和依那西普。二次分析结果一致,布罗达鲁单抗最有效,其次为依奇珠单抗和司库奇尤单抗。

要点

  • 布罗达鲁单抗在52周时达到PASI应答(含完全清除)的可能性高于对照药物。
  • 司库奇尤单抗疗效优于乌司奴单抗,二者均优于依那西普。
  • 二次分析中依那西普和阿普司特预期的长期疗效最低。

核心结论

  • 结果提示布罗达鲁单抗在52周时与对照药物相比,获得持续PASI应答(包括完全清除)的可能性更高。
  • 需要进一步的长期活性对照随机对照试验数据,以更好地评估各疗法间的相对疗效。

研究设计与样本

  • 系统评价与网络Meta分析,纳入报告PASI 75、PASI 90和PASI 100应答的研究。
  • 共识别24项报告40-64周结局的研究,但因研究设计异质性仅能合成17项。
  • 主要分析纳入4项52周随机对照试验,采用贝叶斯多项似然模型(probit链接),尽可能使用意向性治疗且无应答者填补的数据。
  • 二次分析纳入额外13项研究和4种疗法(阿达木单抗、阿普司特、英夫利西单抗和依奇珠单抗),通过将活性干预的长期结局与从诱导期外推的安慰剂结局比较。

主要发现

  • 主要分析中,布罗达鲁单抗显著优于司库奇尤单抗、乌司奴单抗和依那西普。
  • 司库奇尤单抗疗效优于乌司奴单抗,二者均优于依那西普。
  • 二次分析结果与主要分析一致:布罗达鲁单抗最有效,其次为依奇珠单抗和司库奇尤单抗,然后为乌司奴单抗、英夫利西单抗和阿达木单抗。
  • 依那西普和阿普司特预期的长期疗效最低。
  • 排除生物制剂暴露史低的研究后,结果相似。

关键数值与推荐

  • 主要分析基于4项52周随机对照试验的PASI 75、PASI 90和PASI 100应答。
  • 二次分析纳入13项额外研究及4种额外疗法(阿达木单抗、阿普司特、英夫利西单抗、依奇珠单抗)。
  • 研究设计异质性导致24项研究中仅17项可合成。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究设计异质性导致仅能合成24项研究中的17项。
  • 需要进一步的长期活性对照随机对照试验数据,以更好地评估各疗法间的相对疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with moderate-to-severe psoriasis require long-term treatment, yet few trials compare outcomes beyond a short-term induction period. Quantitative comparisons of long-term outcomes in patients with psoriasis are limited. To our knowledge, no network meta-analysis (NMA) of such data has been performed. OBJECTIVE: To compare novel systemic therapies, both biologic and non-biologic, approved for moderate-to-severe psoriasis by conducting a systematic review (SR) and NMA of Psoriasis Area and Severity Index (PASI) outcomes measured at or around 1 year. METHODS: An SR was conducted to identify studies reporting PASI 75, PASI 90 and PASI 100 responses. Feasibility of an NMA on maintenance phase endpoints was assessed and sources of heterogeneity considered. Data appropriate for analysis were modelled using a Bayesian multinomial likelihood model with probit link. Wherever possible, data corresponding to an intention-to-treat approach with non-responder imputation were used. RESULTS: Twenty-four studies reporting outcomes at 40-64 weeks were identified, but heterogeneity in study design allowed synthesis of only 17. Four 52-week randomized controlled trials (RCTs) comprised the primary analysis, which found brodalumab was significantly more efficacious than secukinumab, ustekinumab and etanercept. Secukinumab was also more efficacious than ustekinumab and both outperformed etanercept. In a secondary analysis, evidence from 13 additional studies and 4 further therapies (adalimumab, apremilast, infliximab and ixekizumab) was included by comparing long-term outcomes from active interventions to placebo outcomes extrapolated from induction. Results were consistent with the primary analysis: brodalumab was most effective, followed by ixekizumab and secukinumab, then ustekinumab, infliximab and adalimumab. Etanercept and apremilast had the lowest expected long-term efficacy. Results were similar when studies with low prior exposure to biological therapies were excluded. CONCLUSION: Results suggest that brodalumab is associated with a higher likelihood of sustained PASI response, including complete clearance, at week 52 than comparators. Further long-term active-comparator RCT data are required to better assess relative efficacy across therapies.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Sawyer LM, Cornic L, Levin LÅ, et al. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol. 2018. PMID: 30289198. doi:10.1111/jdv.15277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。